ReviewJournal of clinical medicine2024
Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Social alienation among people with bladder cancer: A combined structural equation modeling and fuzzy-set qualitative comparative analysis.Asia-Pacific journal of oncology nursing · 2026Article
- Epirubicin-Induced Upregulation of miR-143-3p and miR-145 Enhances Cytotoxicity in MCF-7, MDA-MB-231, and BT-474 Breast Cancer Cell Lines.Biochemical genetics · 2026Article
- Unveiling the Chemical Composition and Biological Activity of Extracts from the Antarctic YeastMolecules (Basel, Switzerland) · 2026Article
- FDA approval of mitomycin hydrogel (Zusduri): a new non-surgical era for non-muscle-invasive bladder cancer (NMIBC).Annals of medicine and surgery (2012) · 2026Article
- Two different protocols in single, immediate, postoperative intravesical chemotherapy after transurethral resection in suspected, low-risk, non-muscle-invasive bladder cancer.International urology and nephrology · 2026Article
- Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.Cancers · 2025Review
- The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.iScience · 2025Article
- Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years.International urology and nephrology · 2025Article
- Optimizing chemotherapy outcomes: The role of mindfulness in Epirubicin treatment for urinary tumors.World journal of psychiatry · 2025Article
- From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.